The disease's progression itself appeared to halt
No Brasil, a medicina avança por caminhos antes considerados marginais: a Anvisa aprovou mais um medicamento à base de canabidiol, elevando para 23 o total de produtos canábicos regulamentados desde 2015. Esse movimento reflete não uma ruptura, mas uma consolidação gradual — a transformação de uma planta historicamente estigmatizada em ferramenta terapêutica legítima, disponível em farmácias mediante receita médica. O que está em jogo não é apenas um novo produto nas prateleiras, mas a redefinição contínua dos limites da medicina oficial diante do sofrimento humano.
- A aprovação do Canabidiol Ease Labs 100mg/ml pela Anvisa acrescenta mais um produto a uma lista que cresce com ritmo crescente — sete aprovações apenas entre fevereiro e maio deste ano.
- A tensão entre estigma histórico e evidência clínica ainda permeia o debate, mas o arcabouço regulatório brasileiro trata esses medicamentos com o mesmo rigor exigido de qualquer outro fármaco convencional.
- Pacientes com Parkinson, epilepsia, esclerose múltipla e dor crônica oncológica já acessam esses tratamentos por prescrição, sinalizando que a medicina canábica deixou o campo experimental para o clínico.
- Um estudo da Unila com paciente de 78 anos revelou reversão significativa de sintomas do Alzheimer após uso de óleo de cannabis — memória, humor, sono e progressão da doença responderam de forma surpreendente.
- A comunidade médica e regulatória não questiona mais se o cannabis tem lugar na medicina brasileira, mas até onde esse lugar se estende — e a resposta está sendo escrita caso a caso, aprovação por aprovação.
Na segunda-feira, 28 de novembro, a Anvisa autorizou mais um medicamento canábico para as farmácias brasileiras: o Canabidiol Ease Labs, solução oral com 100mg/ml de canabidiol fabricada pela Ease Labs Laboratório Farmacêutico. O produto segue as exigências regulatórias do país — THC limitado a 0,2% e dispensação apenas mediante receita azul Tipo B. Com essa aprovação, o Brasil chega a 23 medicamentos canábicos autorizados desde 2015, sendo 14 à base de canabidiol e 9 de extrato integral de cannabis.
O ritmo das aprovações acelerou visivelmente: só no primeiro semestre de 2022, sete novos produtos foram liberados, incluindo diferentes formulações de extrato de Cannabis Sativa produzidas por Greencare e Mantecorp Farmasa. As indicações terapêuticas já consolidadas abrangem Parkinson, esclerose múltipla, epilepsia, artrite e dor crônica associada ao câncer — condições em que os tratamentos convencionais frequentemente se mostram insuficientes ou carregam efeitos adversos significativos.
Mas é no horizonte que a discussão se torna mais instigante. Pesquisadores da Unila, em Foz do Iguaçu, acompanharam um paciente de 78 anos com Alzheimer tratado com óleo de cannabis. Os resultados chamaram atenção: houve reversão expressiva de sintomas, com melhora no humor, no sono, na memória e, sobretudo, na progressão da doença — que se estabilizou em vez de avançar. Um único caso não reescreve a ciência, mas abre uma pergunta que a medicina não pode ignorar: até onde o alcance terapêutico do cannabis pode chegar em doenças neurodegenerativas que ainda resistem a outras intervenções?
Brazil's health regulator took another step into cannabis medicine on Monday, November 28th, when Anvisa approved a new pharmaceutical product for pharmacy shelves across the country. The medication, called Canabidiol Ease Labs, is manufactured by Ease Labs Laboratório Farmacêutico as an oral solution containing 100 milligrams of cannabidiol per milliliter. Like all cannabis-derived medicines approved in Brazil, it must meet strict standards: the THC content cannot exceed 0.2 percent, keeping the psychoactive compound at negligible levels. Patients will need a blue Type B prescription to obtain it, marking another addition to the country's growing arsenal of regulated cannabis therapeutics.
This approval brings Brazil's total count of authorized cannabis medications to 23 since the first one was cleared in 2015. The breakdown reflects the regulator's measured approach: fourteen products are cannabidiol-based like the newly approved Ease Labs formulation, while nine are full cannabis extract preparations. Between February and May of this year alone, Anvisa greenlit seven more products, including three different formulations of Cannabis Sativa extract at 160.32 milligrams per milliliter, manufactured by Greencare and Mantecorp Farmasa. The pace of approvals suggests both growing pharmaceutical interest and accumulating clinical evidence supporting these treatments.
The medicines address a range of serious conditions. Doctors prescribe them for Parkinson's disease, multiple sclerosis, epilepsy, and arthritis. They also serve patients managing chronic pain from cancer, where conventional painkillers may prove insufficient or carry unacceptable side effects. The regulatory framework treats these not as experimental compounds but as legitimate pharmaceuticals, subject to the same oversight as any other medication dispensed through formal channels.
Recent research has begun to hint at even broader applications. A study conducted by Unila, the Federal University of Latin American Integration in Foz do Iguaçu, followed a 78-year-old patient who received cannabis oil treatment for Alzheimer's disease. The results were striking enough to merit attention: the patient experienced significant reversal of Alzheimer's symptoms. Beyond the headline finding, the clinical picture improved across multiple dimensions. His mood stabilized. His sleep patterns normalized. His memory showed measurable gains. Most tellingly, the disease's progression itself appeared to halt, remaining stable rather than advancing as Alzheimer's typically does.
One case study cannot rewrite medical understanding, and researchers know this. But it opens a door. It suggests that cannabis-based medicines might eventually address neurodegenerative conditions that have resisted other interventions. For now, the regulatory path remains clear: Anvisa continues evaluating products on their merits, approving those that meet safety and efficacy standards, and making them available through pharmacies under medical supervision. The question facing the medical community is not whether cannabis has a role in Brazilian medicine—that question has been answered. The question now is how far that role extends.
Citações Notáveis
A 78-year-old Alzheimer's patient showed significant reversal of symptoms after cannabis oil treatment, with improvements in mood, sleep, and memory, while disease progression remained stable— Unila (Federal University of Latin American Integration) study findings
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take until 2015 for Brazil to approve the first cannabis medicine, and what changed?
The shift came from accumulating clinical evidence and international precedent. Other countries had already moved forward, and Brazilian researchers began publishing results showing real therapeutic benefit. Regulatory bodies respond to evidence, not ideology, though it takes time.
The THC limit of 0.2 percent seems very strict. Is that enough to prevent any psychoactive effect?
That's precisely the point. At that concentration, THC is essentially inert—you won't get high. The CBD does the therapeutic work. It's a regulatory choice that keeps these medicines in the pharmaceutical space rather than the recreational one.
Why does the Alzheimer's case matter if it's just one patient?
One case doesn't prove anything, but it signals possibility. It tells researchers where to look next. It tells patients and families that their condition might not be a dead end. And it justifies funding for larger studies.
Are these medicines expensive?
The source doesn't say, but typically new pharmaceuticals are costly at first. As more manufacturers enter the market—and you can see that happening with multiple companies now producing approved products—prices tend to fall.
What happens if someone wants cannabis medicine but their doctor won't prescribe it?
They're stuck. The blue prescription requirement means a doctor must be convinced of medical necessity. That's a safeguard, but it also means access depends on physician knowledge and willingness, which varies.